Envarsus XR after kidney transplant to reduce hidden rejection
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and understand English and sign informed consent
- You have end-stage kidney disease and received a primary kidney transplant in your only functioning kidney
- If you could become pregnant, you must use two reliable birth-control methods during the study and for at least 1 year after the infusion
- You have not had any other organ, tissue, or cell transplant before
- You are not allergic to tacrolimus or mycophenolate (Cellcept)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.